Relapsing/refractory HL after autotransplantation: which treatment?
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
25 05 2020
25 05 2020
Historique:
received:
25
05
2020
accepted:
25
05
2020
entrez:
12
6
2020
pubmed:
12
6
2020
medline:
26
3
2021
Statut:
epublish
Résumé
For advanced-stage Hodgkin lymphoma (HL), front-line chemotherapy, alone or in combination with radiotherapy, leads to 5-year progression-free survival (PFS) rates and freedom-from-treatment failure (FFTF) rates of 70-85%, regardless of the chemotherapy regimen applied. Patients with HL experiencing disease progression during or within 3 months of front-line therapy (primary refractory) and patients whose disease relapses after a complete response have a second chance of treatment. The standard of care for relapsed or refractory HL is second-line chemotherapy followed by autologous stem cell transplantation (ASCT), which can induce long-term remission in approximately 40-50% of patients. However, HL recurrence occurs in about 50% of patients after ASCT, usually within the first year, and represents a significant therapeutic challenge. Allogeneic transplantation from HLA-matched donors represents the standard of care for patients with HL relapsing after- or refractory to ASCT.
Identifiants
pubmed: 32525132
doi: 10.23750/abm.v91iS-5.9912
pmc: PMC7944654
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
30-40Références
Acta Haematol. 2004;112(4):194-9
pubmed: 15564730
Bone Marrow Transplant. 2016 Oct;51(10):1313-1317
pubmed: 27183095
J Clin Oncol. 2011 Mar 10;29(8):971-8
pubmed: 21282545
Ann Hematol. 2019 Jun;98(6):1449-1455
pubmed: 30868307
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
PLoS One. 2016 Mar 10;11(3):e0149072
pubmed: 26963909
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
J Clin Oncol. 2013 Feb 10;31(5):e59-63
pubmed: 23269992
Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83
pubmed: 16443515
Eur J Haematol. 2019 Feb;102(2):150-156
pubmed: 30341987
J Clin Oncol. 2018 May 10;36(14):1428-1439
pubmed: 29584546
J Clin Oncol. 2016 Apr 20;34(12):1376-85
pubmed: 26884559
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):333-338
pubmed: 28068241
Am J Hematol. 2015 Jun;90(6):499-503
pubmed: 25720750
Cancer Treat Rev. 2017 Mar;54:99-109
pubmed: 28242522
Eur J Haematol. 2016 Dec;97(6):491-498
pubmed: 27528557
Oncologist. 2015 Mar;20(3):323-8
pubmed: 25669663
Biol Blood Marrow Transplant. 2019 May;25(5):906-911
pubmed: 30481598
Cancer. 2007 Sep 15;110(6):1361-9
pubmed: 17623832
Blood. 2018 Apr 12;131(15):1666-1678
pubmed: 29500174
Haematologica. 2009 Feb;94(2):230-8
pubmed: 19066328
Lancet Oncol. 2016 Sep;17(9):1283-94
pubmed: 27451390
Blood. 2018 Apr 12;131(15):1689-1697
pubmed: 29500170
J Clin Oncol. 2018 Feb 10;36(5):454-462
pubmed: 29360414
Diagnostics (Basel). 2018 Oct 15;8(4):
pubmed: 30326627
Blood. 2017 May 4;129(18):2471-2478
pubmed: 28270452
Chin J Cancer Res. 2017 Dec;29(6):561-571
pubmed: 29353979
J Clin Oncol. 2008 Jan 20;26(3):455-62
pubmed: 18086796
Lancet. 2015 May 9;385(9980):1853-62
pubmed: 25796459
Blood. 2013 Oct 24;122(17):3062-73
pubmed: 24030385
Nucl Med Mol Imaging. 2017 Dec;51(4):371-373
pubmed: 29242737
Blood. 2016 Nov 24;128(21):2489-2496
pubmed: 27574190
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Blood. 2016 Sep 22;128(12):1562-6
pubmed: 27432875
Blood. 2017 Mar 9;129(10):1380-1388
pubmed: 28073785
Blood. 2017 Jul 13;130(2):221-228
pubmed: 28468799
Ann Hematol. 2011 Nov;90(11):1329-36
pubmed: 21437590
Blood. 2018 Jul 5;132(1):9-16
pubmed: 29720488
Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):35-40
pubmed: 30293754
Cochrane Database Syst Rev. 2015 Jan 09;1:CD010533
pubmed: 25572491
Biol Blood Marrow Transplant. 2014 Nov;20(11):1864-8
pubmed: 25008328
J Clin Oncol. 2017 Jul 1;35(19):2125-2132
pubmed: 28441111
Blood. 2012 Jul 19;120(3):560-8
pubmed: 22510871
Ann Hematol. 2015 Sep;94(9):1545-52
pubmed: 26004934
Br J Haematol. 2009 Jul;146(2):158-63
pubmed: 19438504
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):94-102
pubmed: 28816170
Nucl Med Commun. 2018 Jan;39(1):74-82
pubmed: 29189443
Br J Haematol. 2019 Jan;184(1):93-104
pubmed: 30407612
Lancet Oncol. 2017 Apr;18(4):454-463
pubmed: 28236583
Blood. 2012 Jul 19;120(3):691-6
pubmed: 22661699
Ann Hematol. 2016 Apr;95(5):695-706
pubmed: 26931115
Br J Haematol. 2014 Jul;166(1):140-2
pubmed: 24606548
Leuk Lymphoma. 2012 Jun;53(6):1239-41
pubmed: 22132837
Haematologica. 2008 Feb;93(2):257-64
pubmed: 18223284
Crit Rev Oncol Hematol. 2016 May;101:86-92
pubmed: 26971064
Pediatr Blood Cancer. 2019 Mar;66(3):e27539
pubmed: 30426671
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1077-1083
pubmed: 26031367
Bone Marrow Transplant. 2017 Aug;52(8):1208-1211
pubmed: 28581461
Biol Blood Marrow Transplant. 2016 Dec;22(12):2172-2179
pubmed: 27519280
Br J Haematol. 2017 Sep;178(5):709-718
pubmed: 28589704
J Clin Oncol. 2016 Nov 1;34(31):3733-3739
pubmed: 27354476
Am J Hematol. 2018 Jun 8;:
pubmed: 29884994
Am J Hematol. 2017 Sep;92(9):879-884
pubmed: 28512788
Br J Radiol. 2016;89(1061):20150983
pubmed: 27022777
J Hematol Oncol. 2014 Mar 19;7:24
pubmed: 24642247